Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | GNPAT | O15228 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | NMT2 | O60551 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12922150 | 0.93 | SIRT5 (0.54) | SIRT5ALBTLR2NOD1ROCK2 | |
| SCHEMBL13526930 | 0.93 | SIRT5 (0.54) | SIRT5ALBTLR2NOD1ROCK2 | |
| SCHEMBL15176893 | 0.88 | ALB (0.40) | SIRT5ALBTLR2NOD1ROCK2 | |
| SCHEMBL10130532 | 0.84 | SIRT5 (0.60) | SIRT5ALBTLR2NOD1ROCK2 | |
| SCHEMBL10033607 | 0.84 | ALB (0.45) | SIRT5ALBTLR2NOD1ROCK2 | |
| SCHEMBL10027319 | 0.83 | MEN1 (0.52) | SIRT5ALBTLR2NOD1ROCK2 | |
| SCHEMBL24461841 | 0.82 | ALB (0.49) | SIRT5ALBTLR2NOD1ROCK2 | |
| SCHEMBL18174546 | 0.82 | ALB (0.49) | SIRT5ALBTLR2NOD1ROCK2 | |
| SCHEMBL14902998 | 0.82 | CASP2 (0.51) | SIRT5ALBTLR2NOD1EPHX2 | |
| SCHEMBL31626331 | 0.78 | ALB (0.48) | SIRT5ALBTLR2NOD1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176926-A1 | PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1 | AMGEN INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160143852-A1 | LYOPHILIZED THERAPEUTIC PEPTIBODY FORMULATIONS | AMGEN INC. (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160000932-A1 | MODIFIED Fc MOLECULES | AMGEN INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-9139645-B2 | Peptides and related molecules that bind to TALL-1 | AMGEN INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9114175-B2 | Modified Fc molecules | AMGEN INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-8907071-B2 | Toxin peptide therapeutic agents | AMGEN INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140234334-A1 | PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1 | AMGEN INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8513396-B2 | Peptides and related molecules that modulate nerve growth factor activity | AMGEN INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120129771-A1 | PEPTIDES AND RELATED MOLECULES THAT MODULATE NERVE GROWTH FACTOR ACTIVITY | AMGEN INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8143380-B2 | Protein fusions comprising immunoglobulin regions exhibiting improved bioefficacy in multidose administration for use in treatment of infection, cell proliferative, autoimmune and inflammatory disorders | AMGEN INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090318341-A1 | Methods of using OSK1 peptide analogs | AMGEN INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090305399-A1 | DNA encoding OSK1 toxin peptide analogs and vectors and cells for combinant expression | AMGEN INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090299044-A1 | DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression | AMGEN INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090297520-A1 | Methods of using conjugated toxin peptide therapeutic agents | AMGEN INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090291885-A1 | Conjugated toxin peptide therapeutic agents | AMGEN INC. | 2009-11-26 | — | — | US | disclosed |
| US-20090286964-A1 | Modified Fc molecules | AMGEN INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090281286-A1 | Modified Fc molecules | AMGEN INC. | 2009-11-12 | — | — | US | disclosed |
| US-20090281028-A1 | OSK1 peptide analogs and pharmaceutical compositions | AMGEN INC. | 2009-11-12 | — | — | US | disclosed |
| US-20090258017-A1 | Lyophilized therapeutic peptibody Formulations | AMGEN INC. | 2009-10-15 | — | — | US | disclosed |
| US-20090234104-A1 | Modified Fc molecules | AMGEN INC. | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281028-A1 | OSK1 peptide analogs and pharmaceutical compositions | CASK, OSBPL3, OSBP2 | SIRT5 4571/4885ALB 4475/4885TLR2 546/4885 |
| US-20140234334-A1 | PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1 | IGSF11, FCGR1A, FCGR3B | SIRT5 4787/4885ALB 2691/4885TLR2 1758/4885 |
| US-20090286964-A1 | Modified Fc molecules | FCGR3B, FCGR2A, FCGR1A | SIRT5 3063/4885ALB 456/4885TLR2 517/4885 |
| US-20160176926-A1 | PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1 | IGSF11, FCGR1A, FCGR3B | SIRT5 4799/4885ALB 2746/4885TLR2 1651/4885 |
| US-20090281286-A1 | Modified Fc molecules | FCGR3B, FCGR2A, FCGR1A | SIRT5 3063/4885ALB 456/4885TLR2 517/4885 |
| US-20090291885-A1 | Conjugated toxin peptide therapeutic agents | CASK, ANTXR2, TNFSF10 | SIRT5 4677/4885ALB 4193/4885TLR2 358/4885 |
| US-20090297520-A1 | Methods of using conjugated toxin peptide therapeutic agents | CASK, OXSR1, PBK | SIRT5 4698/4885ALB 4264/4885TLR2 437/4885 |
| US-20090305399-A1 | DNA encoding OSK1 toxin peptide analogs and vectors and cells for combinant expression | CASK, OXSR1, TESK1 | SIRT5 4592/4885ALB 4724/4885TLR2 576/4885 |
| US-20090258017-A1 | Lyophilized therapeutic peptibody Formulations | VIP, CRYAB, AVPR1B | SIRT5 955/4885ALB 103/4885TLR2 2514/4885 |
| US-20120129771-A1 | PEPTIDES AND RELATED MOLECULES THAT MODULATE NERVE GROWTH FACTOR ACTIVITY | NGF, NGFR, BDNF | SIRT5 4276/4885ALB 2784/4885TLR2 843/4885 |
| US-20160000932-A1 | MODIFIED Fc MOLECULES | FCGR1A, FCGRT, FCGR2A | SIRT5 4384/4885ALB 645/4885TLR2 651/4885 |
| US-20090318341-A1 | Methods of using OSK1 peptide analogs | OSBPL3, CASK, OXSR1 | SIRT5 4556/4885ALB 4591/4885TLR2 755/4885 |
| US-20090234104-A1 | Modified Fc molecules | FCGR3B, FCGR2A, FCGR1A | SIRT5 3063/4885ALB 456/4885TLR2 517/4885 |
| US-20160143852-A1 | LYOPHILIZED THERAPEUTIC PEPTIBODY FORMULATIONS | VIP, CRYAB, AVPR1B | SIRT5 955/4885ALB 103/4885TLR2 2514/4885 |
| US-20090299044-A1 | DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression | CASK, OXSR1, PBK | SIRT5 4700/4885ALB 4368/4885TLR2 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.